Lexicon Pharmaceuticals (LXRX) rallied strongly today after the European Medicines Agency’s Committee for Medicinal Product for Human Use gave LXRX’s Zynquista a positive mention. Zynquista is a joint development between Lexicon and Sanofi. Zynquista’s application for approval in the United States and Europe has been accepted and is currently under review. Here’s a recap.
Read Article
We choose to let our members and students speak for themselves. We do not actively solicit testimonials, no compensation has been paid for any testimonial, and testimonials are not necessarily representative of the experience of all students. All monetary claims made in testimonials that you see depicted in our marketing material have been verified by Prosper Trading Academy and attested to by the members that have given them. Verified testimonials encompass “experience” reviews that highlight the personal experiences of working with our team and “performance” testimonials where we verify trading success of students who have enrolled in our programs.Given the broad reach of the internet, testimonials and reviews of our programs that we have not been able to verify can be found on various websites across the internet which are beyond our editorial control. While we do very much enjoy hearing positive things from our students and it is critical to our mission that everyone is satisfied with their journey with Prosper, we encourage you to take both verified and unverified testimonials for what they are.